Obstetrics/Gynecology
RSSArticles
-
Internal Medicine Alert - Full February 15, 2014 Issue in PDF
-
New Oral Anticoagulants Poised to Alter Approach to AF
-
What Medical Condition Does this Patient Have?
-
Dapagliflozin Tablets (Farxiga)
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga. -
Effect of Vitamin E and Memantine in Alzheimer's Disease
Among patients with mild-to-moderate Alzheimer's disease, 2000 IU/d of vitamin E resulted in a slower functional decline and a decrease in the caregiver burden. -
Spironolactone for Heart Failure
The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia. -
The 21/7 Combined OCP: Is It Time to Abandon This Formulation?
-
OB/GYN Clinical Alert - Full April 2014 Issue in PDF
-
Continuous Use of Non-androgenic OC Improves Endometriosis Pain and Endometrioma Reoccurrence
Compared to cyclic use, a drospirenone-containing oral contraceptive pill used in a continuous fashion after the removal of an endometrioma is associated with a reduction in dysmenorrhea, non-menstrual pelvic pain, and reoccurrence of endometrioma formation. -
Annual Mammography Screening: The Debate Continues
Although annual screening mammography did increase the detection rate of non-palpable tumors, it did not reduce mortality from breast cancer over 25 years of follow-up.